FDA Prepares to Walk the Opiate REMS Line

Attendees at FDA’s meeting of the Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees in late July will be armed with the agency’s 374-page “brief”-ing on a possible Risk Evaluation and Mitigation Strategy (REMS) for prescription opioids.

Read more ›